The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.
Mammary Cancer|Lymphoma|Bone Tumour|Gynecological Tumors
DRUG: PEG-rhG-CSF
Incidence of febrile neutropenia (FN), 30days after PEG-rhG-CSF administration
The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.